What this study adds:
- The feasibility of TDM of sunitinib in patients with metastatic renal
cell carcinoma (mRCC) was evaluated
- Optimal steady-state trough concentration of sunitinib was found to
lie between 60.75-82.3 ng/ml
- >50% of patients had concentrations outside the optimal
range, hence TDM is likely to improve safety and efficacy of sunitinib
in mRCC